Show simple item record

Subcutaneous epcoritamab combined with rituximab plus lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update

dc.contributor.authorLorenzo, F.
dc.contributor.authorSirpa, L.
dc.contributor.authorWahlin, B. E.
dc.contributor.authorMarcel, N.
dc.contributor.authorChristensen, J. H.
dc.contributor.authorDe, V. S.
dc.contributor.authorHarald, H.
dc.contributor.authorLinton, Kim M
dc.contributor.authorAqeel, A.
dc.contributor.authorWang, L. W.
dc.contributor.authorMinh, D.
dc.contributor.authorBrian, E.
dc.contributor.authorDavid, B.
dc.date.accessioned2022-11-30T10:21:34Z
dc.date.available2022-11-30T10:21:34Z
dc.date.issued2022en
dc.identifier.citationLorenzo F, Sirpa L, Wahlin BE, Marcel N, Christensen JH, De VS, et al. Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update. American journal of hematology. 2022 Oct;97:S31-S. PubMed PMID: WOS:000866743000051.en
dc.identifier.urihttp://hdl.handle.net/10541/625843
dc.titleSubcutaneous epcoritamab combined with rituximab plus lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial updateen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLymphoma Service, Memorial Sloan Kettering Cancer Center, New York,New York, USA;en
dc.identifier.journalAmerican Journal of Hematologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record